Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 19 | 2023 | 2796 | 2.760 |
Why?
|
| Methotrexate | 9 | 2023 | 999 | 1.790 |
Why?
|
| Allopurinol | 4 | 2023 | 54 | 1.120 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 2 | 2020 | 197 | 0.980 |
Why?
|
| Antimetabolites, Antineoplastic | 7 | 2023 | 1299 | 0.940 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2022 | 122 | 0.770 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2023 | 113 | 0.750 |
Why?
|
| Eosinophilia | 1 | 2020 | 176 | 0.650 |
Why?
|
| Ketones | 1 | 2018 | 54 | 0.630 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2017 | 12 | 0.630 |
Why?
|
| Furans | 1 | 2018 | 104 | 0.620 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 321 | 0.590 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 598 | 0.590 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2017 | 83 | 0.580 |
Why?
|
| Sarcoma, Ewing | 1 | 2019 | 406 | 0.540 |
Why?
|
| Translocation, Genetic | 1 | 2020 | 1245 | 0.500 |
Why?
|
| Histiocytosis, Sinus | 1 | 2015 | 86 | 0.500 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 10035 | 0.480 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 534 | 0.480 |
Why?
|
| Child | 20 | 2023 | 29154 | 0.450 |
Why?
|
| Vincristine | 1 | 2017 | 1511 | 0.440 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2022 | 305 | 0.440 |
Why?
|
| Sirolimus | 2 | 2022 | 814 | 0.430 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 402 | 0.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2022 | 15862 | 0.410 |
Why?
|
| Leukemia | 1 | 2020 | 1635 | 0.410 |
Why?
|
| Child, Preschool | 10 | 2020 | 16273 | 0.400 |
Why?
|
| Infant | 8 | 2022 | 13310 | 0.390 |
Why?
|
| Salvage Therapy | 1 | 2019 | 2054 | 0.390 |
Why?
|
| Mercaptopurine | 4 | 2022 | 130 | 0.380 |
Why?
|
| Algorithms | 2 | 2018 | 3890 | 0.370 |
Why?
|
| Nucleosides | 1 | 2009 | 60 | 0.350 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 1375 | 0.340 |
Why?
|
| Adolescent | 13 | 2023 | 31252 | 0.330 |
Why?
|
| Genotype | 1 | 2017 | 4109 | 0.330 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 5178 | 0.330 |
Why?
|
| CpG Islands | 1 | 2010 | 633 | 0.310 |
Why?
|
| Tissue Distribution | 2 | 2019 | 875 | 0.300 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2576 | 0.290 |
Why?
|
| Lymphoma, T-Cell | 1 | 2009 | 361 | 0.280 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2022 | 6915 | 0.270 |
Why?
|
| Maximum Tolerated Dose | 2 | 2019 | 1290 | 0.270 |
Why?
|
| Maintenance Chemotherapy | 2 | 2023 | 202 | 0.240 |
Why?
|
| Humans | 29 | 2023 | 261506 | 0.240 |
Why?
|
| Azacitidine | 1 | 2010 | 1149 | 0.230 |
Why?
|
| Lymphoma | 2 | 2022 | 1467 | 0.230 |
Why?
|
| Thioguanine | 2 | 2022 | 68 | 0.220 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 3101 | 0.220 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 1879 | 0.210 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2022 | 49 | 0.210 |
Why?
|
| Gene Rearrangement | 2 | 2020 | 783 | 0.210 |
Why?
|
| Spinal Cord Diseases | 1 | 2022 | 90 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 4938 | 0.200 |
Why?
|
| Neoplasms | 2 | 2018 | 15193 | 0.200 |
Why?
|
| Male | 14 | 2022 | 123000 | 0.200 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2019 | 193 | 0.180 |
Why?
|
| Sodium Bicarbonate | 1 | 2020 | 59 | 0.180 |
Why?
|
| DNA Methylation | 1 | 2010 | 2669 | 0.180 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 749 | 0.170 |
Why?
|
| Cytarabine | 2 | 2022 | 1973 | 0.170 |
Why?
|
| Phthalazines | 1 | 2019 | 253 | 0.150 |
Why?
|
| Female | 13 | 2020 | 141928 | 0.150 |
Why?
|
| Pharmacogenomic Testing | 1 | 2017 | 46 | 0.150 |
Why?
|
| Vidarabine | 1 | 2022 | 1341 | 0.150 |
Why?
|
| Hypoglycemia | 1 | 2018 | 213 | 0.150 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 14289 | 0.150 |
Why?
|
| Microtubules | 1 | 2018 | 270 | 0.150 |
Why?
|
| Antiemetics | 1 | 2017 | 125 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2016 | 6550 | 0.140 |
Why?
|
| Morpholines | 1 | 2017 | 289 | 0.140 |
Why?
|
| Vomiting | 1 | 2017 | 354 | 0.130 |
Why?
|
| Lymphocyte Transfusion | 1 | 2016 | 175 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 196 | 0.120 |
Why?
|
| Young Adult | 4 | 2023 | 21445 | 0.120 |
Why?
|
| Unrelated Donors | 1 | 2016 | 304 | 0.120 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 14889 | 0.120 |
Why?
|
| Prognosis | 2 | 2019 | 21713 | 0.100 |
Why?
|
| Risk Factors | 2 | 2018 | 17523 | 0.100 |
Why?
|
| Leukemia, T-Cell | 1 | 2009 | 87 | 0.090 |
Why?
|
| DNA Modification Methylases | 1 | 2010 | 172 | 0.090 |
Why?
|
| Splenic Neoplasms | 1 | 2009 | 119 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2023 | 37905 | 0.080 |
Why?
|
| Gene Silencing | 1 | 2010 | 837 | 0.070 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 461 | 0.070 |
Why?
|
| Adult | 3 | 2019 | 77950 | 0.070 |
Why?
|
| Survival Rate | 1 | 2019 | 12221 | 0.070 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8223 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2018 | 12873 | 0.060 |
Why?
|
| Remission Induction | 1 | 2009 | 3569 | 0.060 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 227 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 2265 | 0.050 |
Why?
|
| Creatinine | 1 | 2023 | 531 | 0.050 |
Why?
|
| Etoposide | 1 | 2022 | 870 | 0.050 |
Why?
|
| Bortezomib | 1 | 2022 | 543 | 0.050 |
Why?
|
| Arabinonucleosides | 1 | 2022 | 437 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 249 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 3869 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2011 | 32848 | 0.040 |
Why?
|
| Sodium | 1 | 2020 | 353 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2010 | 9244 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2022 | 1152 | 0.040 |
Why?
|
| Mucositis | 1 | 2017 | 148 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 1678 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 1546 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2017 | 182 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2022 | 3001 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 700 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2017 | 333 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 14551 | 0.030 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 30 | 0.030 |
Why?
|
| Guanine Nucleotides | 1 | 2013 | 23 | 0.030 |
Why?
|
| Xanthine Oxidase | 1 | 2013 | 19 | 0.030 |
Why?
|
| Biotransformation | 1 | 2013 | 93 | 0.030 |
Why?
|
| Thionucleotides | 1 | 2013 | 65 | 0.030 |
Why?
|
| Allografts | 1 | 2016 | 650 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 1382 | 0.030 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 78 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2013 | 425 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 4557 | 0.030 |
Why?
|
| Methyltransferases | 1 | 2013 | 148 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 500 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 3472 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2022 | 10001 | 0.020 |
Why?
|
| Neutropenia | 1 | 2013 | 968 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 739 | 0.020 |
Why?
|
| Recurrence | 1 | 2016 | 4758 | 0.020 |
Why?
|